Safety and Efficacy Study of An Anti-CD38 Antibody Drug Conjugate in Relapsed or Refractory Multiple Myeloma

Trial Details

NCT ID

NCT05565807

Phase

PHASE1 / PHASE2

Sponsor

Zhejiang ACEA Pharmaceutical Co. Ltd.

Status

RECRUITING

Cancer Type

Multiple Myeloma

Interventions

• STI-6129

Locations (sample)

• Beijing, Beijing Municipality, China|39.9075,116.39723
• Beijing, Beijing Municipality, China|39.9075,116.39723
• Guangzhou, Guangdong, China|23.11667,113.25
• Hangzhou, Zhejiang, China|30.29365,120.16142

Key Eligibility Criteria

• Age ≥18 years old, regardless of gender.
• Previously treated with at least three drugs (including PI, IMiD, and anti-CD38 antibody), and relapsed/refractory after the most recent anti-MM th…
• Diagnosis of MM according to IMWG criteria with measurable lesions, meeting at least 1 of the following criteria:
• Serum M protein ≥ 0.5g/dL (≥ 5 g/L); or

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.